Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

A woman is suing a fertility clinic for transferring another couple's embryo into her uterus. They realized the error when ...

Hims & Hers announced its plans to introduce at-home lab testing through its platform. The company has acquired an at-home lab testing ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

The acquisition of Trybe Labs, marketed as Sigmund NJ LLC, will enable Hims & Hers to offer comprehensive whole body testing, including at-home blood draws. This addition to the company’s services is ...

Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

US woman Krystena Murray is suing an IVF clinic after giving birth to a baby which wasn't genetically hers in December 2023.

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

A woman who gave birth to a baby boy that wasn't hers due to an embryo transfer mix-up filed a lawsuit Tuesday against a ...